Novavax, Inc. (NVAX) Stock

Novavax, Inc. (NVAX) is a Healthcare stock trading at $9.14 (as of 2026-06-18), with a market capitalization of $1.80B and a trailing P/E of -26.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of vaccines to prevent infectious diseases. Its pipeline includes NVX‑CoV2373 for COVID‑19, NanoFlu for seasonal influenza, and RSV F protein vaccine candidates for RSV, with collaboration for NVX‑CoV2373 with Takeda.

Valuation — source: SEC EDGAR (first-party)

Price	$9.14
Market Cap	$1.80B
P/E Ratio	-26.8
EV / EBITDA	-33.6
Price / Book	-12.46
Price / Sales	3.02
DCF Value (model)	$-23.99
DCF Upside vs Price	-362.5%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$1.12B
Net Margin	39.2%
Return on Equity	60.7%
Debt / Equity	-2.01
Current Ratio	2.48
Revenue Growth (YoY)	-79.1%
EPS Growth (YoY)	-101.9%

Financial Health — source: SEC EDGAR

Altman Z-Score

-2.00 (distress)

Valuation vs Sector & Industry

Stock P/E	-26.8
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-227.7%
vs Industry	-255.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	SHAH CAPITAL MANAGEMENT ($120.84M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	John Charles Jacobs
Employees	952
Country	US
IPO Date	1995-12-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Inhibrx Biosciences, Inc. (INBX)
• Iovance Biotherapeutics, Inc. (IOVA)
• Sana Biotechnology, Inc. (SANA)
• Pacira BioSciences, Inc. (PCRX)
• Erasca, Inc. (ERAS)
• NovaBridge Biosciences (NBP)
• Intellia Therapeutics, Inc. (NTLA)
• Phibro Animal Health Corporation (PAHC)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.